bioRxiv Science⌕ Search

Biology subjects

Gibbs, B. J.

Publications and source records attributed to Gibbs, B. J..

2 recordsLinked to original sources

Humanized tau and amyloid-β deposition accelerate tau propagation, neuronal cell loss and neurophysiological dysfunction in novel mouse models of primary age-related tauopathy and Alzheimer's disease

In Alzheimers disease (AD), tau pathology arises in entorhinal cortex layer II (ECII) and advances through defined hippocampal circuits to CA1 and connected neocortical regions, yet the determinants of this hierarchical spread remain unclear. We previously established a circuit-defined propagation model by expressing Cre-inducible human P301L 2N4R tau selectively in Wolframin-1 (Wfs1)+ ECII neurons using AAV-FLEX-TauP301L in Wfs1-Cre mice. Here, to test how amyloid-{beta} (A{beta}) and human tau background shape propagation, we generated human MAPT knock-in Wfs1 mice and APPNL-G-F/MAPT double knock-in Wfs1 mice (T-Wfs1 and AT-Wfs1) and induced ECII-restricted TauP301L expression. Three months after injection, phosphorylated or misfolded tau-positive neurons were enriched in proximal CA1 in Wfs1 and T-Wfs1 mice, resembling primary age-related tauopathy, whereas AT-Wfs1 mice showed preferential accumulation near the CA1/subiculum (Sub) boundary, consistent with an AD-like pattern. In T-Wfs1 and AT-Wfs1 mice, tau spread extended through Sub to neocortical regions, and phosphorylated tau accumulated predominantly in excitatory rather than inhibitory neurons. Electrophysiological analyses revealed increased spontaneous neuronal firing and impaired GABAergic transmission in the CA1/Sub boundary and neocortical areas in T-Wfs1 and AT-Wfs1 mice, indicative of impaired GABAergic input and enhanced neuronal excitability in these regions. Together, these data indicate that human MAPT and A{beta} pathology shift the circuit topography of tau propagation and are associated with early network dysfunction, supporting a synergistic interaction that promotes AD-like spread and synaptic imbalance.

neuroscience↗

Proteomic characterization of neuronal extracellular vesicle interactomes in Alzheimer's disease mouse model through TurboID-based proximity labeling

Extracellular vesicles (EVs) are critical mediators of neuronal communication and have been implicated in propagating pathological processes in neurodegenerative diseases, including Alzheimers disease (AD). However, the molecular interactome of neuronal EVs in vivo remains poorly defined. Here, we employed TurboID-CD9-based proximity biotinylation to label and capture EV-interacting proteins in the hippocampus of wild-type (WT) and APPNLGF knock-in AD mouse models. Adeno-associated viral delivery of hSyn1 promoter-driven TurboID-CD9 enabled neuron-specific EV tagging, followed by in vivo biotinylation and affinity purification of labeled proteins. Proteomic analysis using data independent acquisition liquid chromatography - mass spectrometry identified 5,502 proteins, with enriched pathways involving synaptic transmission, vesicle trafficking, and inhibitory neurotransmission. Comparative analyses revealed robust enrichment of GABAergic signaling components, including GABAA receptor subunits (Gabrb3, Gabra1, Gabbr2), Ncam1, and chloride transporters, in both WT and APPNLGF EV interactomes, with additional disease-associated proteins (Mapt, Snca) and potassium channel enrichment observed in APPNLGF mice. Proximity ligation assays validated direct EV-associated biotinylation of Ncam1, Gabrb3, and Gad1, with Gad1 showing significant upregulation in the APPNLGF cohort. In silico HADDOCK docking supported stable interactions between CD9 and these target proteins, revealing plausible EV-protein interfaces. These findings define the in vivo neuronal EV interactome and its remodeling in amyloid pathology, implicating EV-associated GABAergic and ion channel proteins in network excitability regulation. This work establishes a proteomic and structural framework for understanding EV-mediated signaling in health and disease, providing candidate targets for therapeutic modulation of excitatory / inhibitory balance in AD.

neuroscience↗